within
last
decad
new
technolog
develop
implement
employ
light
often
presenc
photosensit
inactiv
pathogen
resid
human
blood
product
purpos
transfus
pathogen
reduct
technolog
attempt
find
proper
balanc
pathogen
kill
cell
qualiti
system
util
variou
chemistri
impact
pathogen
inactiv
also
treatment
affect
plasma
cellular
protein
degre
paper
aim
present
variou
chemic
mechan
pathogen
reduct
transfus
medicin
current
practic
develop
peopl
util
light
medic
therapi
throughout
histori
earli
greek
civil
peopl
attempt
har
light
therapeut
agent
current
treatment
hyperbilirubimia
tcell
lymphoma
even
graftversushost
diseas
gvhd
involv
extracorpor
photopheresi
well
establish
within
last
decad
new
technolog
develop
implement
employ
light
often
presenc
photosensit
inactiv
pathogen
resid
human
blood
product
purpos
transfus
blood
donor
screen
nucleic
acid
test
nat
variou
pathogen
implement
reduc
risk
transfus
transmit
diseas
still
residu
risk
blood
safeti
regard
emerg
pathogen
region
previous
endem
infect
dengu
viru
parasit
trypanosoma
cruzi
caus
agent
chaga
diseas
pathogen
reduct
particularli
valuabl
unknown
previous
unidentifi
pathogen
sar
west
nile
viru
also
emerg
blood
suppli
littl
advanc
warn
blood
bank
health
organ
must
react
quickli
scenario
identifi
agent
form
strategi
prevent
contamin
blood
suppli
develop
new
screen
test
necessari
second
test
methodolog
continu
becom
sensit
alway
period
time
pathogen
undetect
window
period
test
procedur
limit
test
sensit
furthermor
blood
safeti
also
threaten
residu
white
blood
cell
exist
even
leukoreduct
techniqu
employ
contrast
implement
pathogen
reduct
technolog
prt
enabl
blood
provid
take
proactiv
approach
blood
safeti
inactiv
pathogen
might
exist
blood
product
therebi
prevent
infect
recipi
hand
pathogen
inactiv
potenti
pose
sever
challeng
divers
infecti
agent
requir
techniqu
technolog
broad
spectrum
activ
effect
envelop
nonenvelop
virus
gramposit
gramneg
bacteria
includ
sporeform
agent
parasit
white
blood
cell
techniqu
common
requir
chemic
reaction
biolog
product
surpris
current
techniqu
shown
caus
variou
degre
cellular
protein
damag
well
degre
toxic
treat
product
major
prt
design
target
nucleic
acid
pathogen
disrupt
function
platelet
plasma
red
blood
cell
requir
genom
dna
viabl
howev
beyond
target
damag
pathogen
genet
materi
secondari
damag
also
incur
protein
membran
molecul
potenti
lead
degrad
blood
product
qualiti
obviou
exampl
develop
vivex
low
molecular
weight
reduct
compound
coval
link
nucleic
acid
work
reduc
pathogen
load
presenc
red
blood
cell
howev
also
unintend
consequ
caus
immun
modul
form
neoantigen
new
antibodi
compound
form
antibodi
alreadi
present
individu
also
target
compound
thu
find
balanc
suffici
pathogen
reduct
accept
product
qualiti
critic
number
prt
introduc
attempt
find
proper
balanc
pathogen
kill
product
qualiti
sever
technolog
commerci
avail
technolog
affect
cell
compon
protein
factor
plasma
differ
way
myriad
review
discuss
product
qualiti
pusblish
paper
aim
present
variou
chemic
mechan
pathogen
reduct
transfus
medicin
current
practic
develop
vast
major
prt
util
photosensit
molecul
absorb
light
energi
induc
excit
state
allow
undergo
chemic
reaction
suscept
molecul
process
also
util
photodynam
therapi
activ
photosensit
two
type
reaction
known
occur
absenc
oxygen
type
reaction
take
place
involv
direct
electron
transfer
photosensit
target
case
dna
reaction
typic
result
format
ion
radic
propag
chemic
reaction
ultim
result
reduct
pathogen
load
presenc
oxygen
type
ii
reaction
occur
lead
format
singlet
oxygen
speci
highli
activ
react
dna
molecul
also
result
reduct
pathogen
load
type
photosensit
molecul
dictat
wavelength
light
energi
requir
promot
photochem
reaction
methylen
blue
therapeut
capabl
methylen
blue
mb
long
known
date
back
centuri
use
treat
malaria
still
investig
use
plasmodium
spp
mb
long
use
treat
methemoglobinemia
reduct
properti
low
dose
mb
investig
photodynam
treatment
cancer
dna
damag
gener
oxid
stress
result
apoptosi
cancer
cell
combin
light
mb
also
use
treat
resist
plaqu
psoriasi
aidsrel
kaposi
sarcoma
inactiv
staphylococcu
aureu
phenothiazin
dye
includ
mb
known
virucid
properti
year
use
combin
visibl
light
includ
inactiv
west
nile
viru
duck
hepat
b
adenoviru
vector
hepat
c
methylen
blue
either
intercal
dna
associ
outer
helix
depend
mg
ionic
strength
concentr
presenc
oxygen
reactiv
oxygen
speci
gener
oxygendeplet
environ
direct
electron
transfer
like
respons
phosphodiest
bond
cleavag
result
strand
breakag
guanineresidu
presenc
visibl
wavelength
light
mb
peak
absorpt
nm
type
redox
type
ii
photooxid
reaction
occur
howev
thought
type
ii
photodynam
reaction
primarili
respons
pathogen
reduct
reaction
occur
excit
mb
also
lead
reduct
leukomethylen
blue
demethyl
azur
azur
b
thionin
result
mb
activ
lead
predominantli
guanosin
oxid
via
type
ii
pathway
chang
dna
ultim
prevent
replic
pathogen
fig
origin
process
util
mb
ffp
develop
spring
germani
use
initi
freezethaw
step
inactiv
wbc
ad
amount
mb
specif
plasma
unit
give
precis
final
concentr
mb
today
mb
use
commerci
activ
compound
theraflex
mb
plasma
system
macopharma
tourco
franc
dissolv
anhydr
mb
pill
lg
final
concentr
lm
plasma
mixtur
illumin
visibl
light
nm
depend
system
use
energi
j
cm
see
tabl
prior
illumin
plasma
product
pass
lm
filter
plasmaflex
macopharma
reduc
level
residu
white
blood
cell
red
blood
cell
platelet
aggreg
intracellular
virus
reduc
level
microparticl
illumin
complet
process
requir
remov
mb
use
blueflex
mb
remov
filter
macopharma
ultim
reduc
residu
mb
concentr
lm
mention
theraflex
system
spring
method
procedur
ident
illumin
time
illumin
sourc
energi
dose
two
method
differ
howev
avail
data
demonstr
method
effect
common
pathogen
includ
hiv
respect
blood
safeti
mb
limit
applic
effect
pathogen
reduc
agent
plasma
mb
phenothiazin
deriv
consequ
high
affin
nucleic
acid
well
surfac
structur
virus
mb
also
known
bind
viral
core
protein
importantli
bacteria
hemoglobin
reduc
mb
leukomb
function
neither
photosensit
dna
intercal
reduc
overal
effect
mb
bacteria
intracellular
pathogen
addit
hydrophil
charact
posit
charg
mb
penetr
cell
membran
therefor
ineffici
inactiv
intracellular
pathogen
rather
mb
remain
local
extern
membran
protein
lipid
result
cellular
damag
photoactiv
underli
reason
mb
use
treatment
plasma
treatment
platelet
red
cell
product
theraflex
claim
effici
viru
reduct
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
cytomegaloviru
cmv
west
nile
viru
wnv
parvoviru
other
less
effect
picornaviru
famili
includ
hepat
viru
hav
polioviru
encephalomyocard
viru
though
known
famili
virus
highli
resist
physiochem
treatment
also
effect
parasit
trypanosoma
cruzi
histor
mb
shown
effect
gramposit
gramneg
bacteria
treat
plasma
use
patient
known
allergi
mb
photoproduct
also
use
patient
known
phosphat
dehydrogenas
defici
may
caus
hemolyt
anemia
patient
addit
concern
respect
mb
ansm
formerli
known
afssap
french
drug
medic
devic
regulatori
agenc
withdrew
mb
plasma
list
approv
blood
product
franc
march
evalu
french
hemovigili
system
ansm
saw
greater
incid
allerg
reaction
mb
plasma
type
plasma
well
greater
variabl
concentr
fibrinogen
mb
plasma
compar
type
plasma
henc
conclud
withdraw
mb
plasma
list
approv
product
light
decis
macopharma
decid
carri
retrospect
post
market
surveil
studi
order
gener
data
demonstr
safeti
effici
theraflex
mbplasma
amotosalen
practic
use
psoralen
conjunct
uva
light
treat
psoriasi
establish
continu
accept
clinic
techniqu
known
puva
psoralen
uva
therapi
puva
therapi
gener
refer
use
psoralen
predecessor
commerci
use
prt
psoralen
amotosalen
ceru
inc
amotosalen
tricycl
molecul
consist
furan
pyron
moieti
howev
amotosalen
design
water
solubl
addit
amin
side
chain
consequ
less
lipophil
hundr
psoralen
natur
synthet
evalu
chemic
biolog
characterist
amotosalen
select
develop
base
activ
varieti
virus
bacteria
maintain
function
properti
platelet
plasma
intercept
system
ceru
corp
concord
ca
util
amotosalen
lm
photosensit
agent
inactiv
pathogen
presenc
uva
nm
j
cm
see
tabl
small
planar
heterocycl
aromat
molecul
psoralen
high
propens
intercal
revers
within
doubl
helic
structur
nucleic
acid
latter
specif
true
amotosalen
carri
cation
charg
physiolog
condit
increas
affin
dna
dna
molecul
neg
charg
uva
activ
coval
crosslink
form
pyrimidin
rna
dna
use
sequenti
cycloaddit
reaction
type
reaction
occur
presenc
light
correct
wavelength
first
photoactiv
amotosalen
form
coval
adduct
either
thymidin
adenin
form
singl
adduct
forc
helic
unwind
nucleic
acid
molecul
unwind
dna
second
adduct
form
presenc
uva
form
crosslink
origin
adduct
rna
second
adduct
form
yield
intrastrand
crosslink
crosslink
prevent
helic
unwind
replic
nucleic
acid
polymeras
numer
monoadduct
crosslink
prevent
replic
ultim
respons
abil
amotosalen
inactiv
pathogen
upon
activ
uva
fig
water
solubl
properti
deriv
addit
titrat
amin
side
chain
amotosalen
penetr
cell
membran
thu
allow
act
upon
intracellular
nucleic
acid
numer
pathogen
allow
intercept
technolog
use
treat
plasma
platelet
product
red
cell
hemoglobin
absorb
uva
prevent
activ
psoralen
illumin
approxim
amotosalen
remain
product
photodegrad
photoproduct
gener
approxim
compris
dimer
wherea
remain
product
coval
bind
high
molecular
weight
lipid
follow
uva
treatment
intercept
system
blood
product
must
filter
remov
psoralen
compound
photoproduct
use
compound
adsorpt
devic
cad
cad
consist
spheric
bead
enclos
polyest
mesh
pouch
within
plastic
contain
matrix
adsorb
unbound
amotosalen
photoproduct
follow
treatment
h
incub
period
cad
devic
effect
reduc
level
residu
wherea
level
major
photoproduct
remain
unbound
reduc
approxim
howev
photoproduct
bound
adduct
remov
cad
devic
intercept
blood
system
demonstr
inactiv
pathogen
vari
degre
except
nonenvelop
virus
hepat
hav
porcin
parvoviru
ppv
model
human
parvoviru
bacteri
spore
resist
treatment
sever
technolog
limit
effect
certain
nonenvelop
virus
demonstr
clinic
transfusionbas
transmiss
hev
occur
via
plasma
product
intercept
also
effect
gramneg
eg
escherichia
coli
serratia
marcescen
gramposit
bacteria
eg
staphylococcu
epidermidi
streptococcu
pyogen
well
select
parasit
includ
plasmodium
falciparum
trypanosoma
cruzi
leishmania
spp
intercept
abl
inactiv
residu
donor
leukocyt
includ
tcell
vitro
studi
demonstr
inhibit
replic
cytokin
synthesi
follow
treatment
intercept
approv
use
place
gamma
irradi
treat
platelet
order
prevent
transfusionassoci
graftversushost
diseas
tagvhd
addit
intercept
treatment
platelet
replac
cmv
serolog
accord
respect
nation
regulatori
author
prevent
transfusiontransmit
cmv
infect
intercept
plasma
unit
may
use
treatment
coagul
factor
antithrombot
protein
defici
well
patient
requir
plasma
exchang
thrombot
thrombocytopen
purpura
ttp
howev
neonat
patient
requir
plasma
transfus
treat
hyperbilirubinemia
receiv
intercept
treat
plasma
devic
emit
light
wavelength
less
nm
uva
combin
amotosalen
treatment
transfus
plasma
product
result
erythema
patient
riboflavin
riboflavin
rb
vitamin
natur
occur
compound
essenti
nutrient
human
member
group
molecul
term
flavin
due
ringmoieti
impart
yellow
color
oxid
molecul
ribo
deriv
ribos
sugar
form
part
structur
flavin
cofactor
wide
varieti
oxid
enzym
remain
bound
enzym
oxidationreduct
reaction
flavin
abl
accept
pair
hydrogen
atom
thu
allow
act
oxid
agent
riboflavin
precursor
flavin
cofactor
vivo
metabol
flavin
adenin
dinucleotid
fad
flavin
mononucleotid
fmn
phosphoryl
form
riboflavin
photochem
mechan
action
riboflavin
mediat
type
type
ii
redox
reaction
upon
activ
uv
light
riboflavin
oxid
guanin
residu
dna
rna
via
direct
electron
transfer
reaction
occur
absenc
oxygen
primari
photoproduct
riboflavin
condit
lumichrom
though
intermedi
metabol
andor
photochem
degrad
product
identifi
includ
formylmethylflavin
ketoflavin
ketoflavin
byproduct
occur
low
concentr
fig
riboflavin
abl
penetr
mitochondri
membran
may
facilit
mitochondri
function
role
flavin
molecul
extens
toxicolog
profil
riboflavin
qualifi
unit
state
feder
drug
agenc
fda
gra
compound
gener
regard
safe
cfr
usfad
us
nation
archiv
record
administr
electron
code
feder
regul
photoproduct
present
broad
rang
food
natur
product
wide
use
supplement
phototherapeut
treatment
jaundic
neonat
riboflavin
may
also
use
alon
combin
magnesium
citrat
coenzym
prevent
migrain
riboflavin
lm
photosensit
agent
mirasol
pathogen
reduct
technolog
system
terumo
bct
lakewood
co
use
treat
platelet
plasma
product
develop
whole
blood
compon
separ
ongo
use
technolog
mirasol
system
platelet
plasma
platelet
plasma
product
illumin
j
ml
uv
light
nm
see
tabl
apheresi
collect
separ
blood
product
whole
blood
extens
toxicolog
studi
perform
terumo
bct
organ
indic
toxicolog
concern
transfus
uv
treat
blood
presenc
riboflavin
note
riboflavin
recogn
gra
compound
fda
thu
addit
remov
step
requir
treatment
immedi
readi
transfus
whether
treat
product
platelet
plasma
whole
blood
mirasol
system
also
develop
treatment
whole
blood
product
yet
avail
sale
date
public
system
util
technolog
uv
light
nm
plu
riboflavin
illumin
whole
blood
product
j
ml
rbc
uv
light
dose
depend
upon
volum
hematocrit
blood
product
develop
whole
blood
system
would
facilit
process
treatment
compon
process
singl
treatment
could
theoret
result
three
prttreat
product
could
immedi
transfus
mirasol
prt
system
demonstr
inactiv
pathogen
vari
degre
includ
nonenvelop
virus
hepat
hav
log
reduct
porcin
parvoviru
ppv
log
reduct
model
human
parvoviru
howev
like
intercept
bacteri
spore
demonstr
resist
treatment
technolog
mirasol
also
effect
gramneg
eg
escherichia
coli
pseudomona
aeruginosa
gramposit
bacteria
eg
staphylococcu
epidermidi
aureu
mrsa
strain
well
select
parasit
includ
plasmodium
falciparum
trypanosoma
cruzi
leishmania
donovani
addit
abl
inactiv
residu
donor
leukocyt
includ
tcell
mirasol
system
treatment
also
use
combin
leukoreduct
use
instead
cmv
test
prevent
transfusiontransmit
cmv
infect
vitro
studi
mirasol
system
determin
tcell
prolifer
complet
inhibit
limit
dilut
assay
lda
studi
tcell
viabil
mirasol
treatment
reduc
limit
detect
assay
j
ml
normal
energi
dose
log
reduct
intercept
system
treatment
mirasol
system
use
instead
gamma
irradi
prevent
tagvhd
vivo
studi
demonstr
mirasol
system
prevent
product
cytokin
tnfa
ifnc
respons
anti
lp
stimul
wbc
deriv
cytokin
detect
mirasol
treat
platelet
unit
day
storag
data
suggest
mirasol
treatment
may
prevent
febril
nonhemolyt
transfus
reaction
interestingli
mirasol
may
also
prevent
alloimmun
studi
shown
impair
bind
mirasol
treat
leukocyt
respond
cell
antigen
present
mirasol
treatment
prolifer
respond
cell
mix
leukocyt
cultur
possibl
explan
may
mirasoltr
cell
significantli
reduc
express
sever
surfac
receptor
involv
tcell
activ
adhes
specif
hladr
icam
addit
inhibit
cell
cell
interact
alloantibodi
format
rat
transfus
model
findingwhich
could
signific
implic
patient
care
gener
transfus
practic
transplant
patient
multiplytransfus
individu
uvc
theraflexuvplatelet
system
macopharma
photoact
pathogen
reduct
platform
includ
addit
photosensit
compound
make
simpl
process
pharmacolog
standpoint
process
use
uvc
nm
pathogen
inactiv
sourc
howev
due
short
wavelength
light
attribut
uvc
effect
medium
rel
transpar
consequ
reactiv
quench
turbid
proteincontain
solut
thu
use
inactiv
apheresi
buffi
coat
platelet
product
platelet
addit
solut
macopharma
specif
direct
use
ssp
technolog
agit
product
illumin
essenti
ensur
blood
product
homogen
expos
light
uvc
act
directli
nucleic
acid
cycloaddit
mechan
gener
thymin
dimer
specif
cyclobutan
pyrimidin
pyrimidinepyrimidon
dimer
ultim
prevent
dna
polymeras
proceed
transcript
demonstr
treatment
wavelength
nm
energi
dose
j
cm
result
effect
level
viru
bacteria
parasit
reduct
maintain
accept
level
platelet
cell
qualiti
photosensit
compound
ad
blood
product
filtrat
requir
treatment
theraflex
system
fig
theraflex
uvplatelet
system
current
clinic
evalu
avail
routin
use
like
intercept
mirasol
theraflex
system
may
use
replac
gamma
irradi
prevent
tagvhd
mix
lymphocyt
cultur
assay
appreci
prolifer
compar
untreat
sampl
similarli
less
hthymidin
incorpor
stimul
assay
uvc
compar
gamma
irradi
comparison
numer
photoindepend
method
pathogen
inactiv
develop
brief
descript
techniqu
provid
solvent
deterg
techniqu
use
nonion
deterg
disrupt
lipid
membran
envelop
virus
wide
use
limit
applic
sole
use
treat
plasma
product
due
mechan
action
solventdeterg
techniqu
use
treat
cellular
product
reagent
would
destroy
lipid
bilay
cell
nonvolatil
organ
solvent
facilit
sequestr
membran
lipid
viral
envelop
separ
colloid
phase
thu
caus
damag
disrupt
viral
function
techniqu
ineffect
nonenvelop
virus
hav
hev
parvoviru
shown
disrupt
complement
activ
plasma
gramneg
bacteria
remov
solvent
deterg
requir
oil
extract
chromatographi
prior
transfus
product
solventdeterg
plasma
avail
commerci
pool
product
octapla
octapharma
europ
unit
state
though
treatment
process
vari
somewhat
two
region
plasma
product
prionreduc
advertis
safe
risk
trali
accord
manufactur
pool
plasma
numer
donor
result
signific
dilut
antigranulocyt
hna
antihuman
lymphocyt
antigen
hla
antibodi
subsequ
reduc
risk
transfus
reaction
trali
specif
lot
octapla
manufactur
pool
plasma
singl
abo
blood
group
b
ab
frozen
plasma
unit
thaw
pool
sodium
dihydrogen
phosphat
dihydr
ad
buffer
prevent
increas
ph
due
loss
co
plasma
filter
next
plasma
pool
treat
tri
nbutyl
phosphat
tnbp
polyoxyethyleneptoctylphenol
triton
h
inactiv
envelop
virus
tnbp
use
remov
lipid
pathogen
membran
tritonx
deterg
stabil
tnbp
disrupt
lipid
bilay
follow
treatment
compound
remov
first
oil
solid
phase
extract
procedur
glycin
ad
plasma
adjust
osmol
run
column
fill
affin
ligand
resin
select
bind
prion
protein
misfold
protein
caus
variant
creutzfeldtjakob
diseas
vcjd
steril
filtrat
product
frozen
store
pool
separ
process
gener
standard
product
nanofiltr
use
filter
blood
bank
use
larg
remov
white
blood
cell
howev
concept
studi
regard
pathogen
reduct
use
filter
pore
size
nm
remov
pathogen
base
sizeexclus
principl
due
small
natur
pore
size
techniqu
applic
plasma
platelet
red
cell
would
also
sequest
filter
recent
data
demonstr
recoveri
plasma
protein
activ
use
method
howev
high
molecular
weight
von
willebrand
factor
speci
remov
filtrat
requir
remov
viru
filter
remov
prion
also
great
interest
prt
technolog
target
nucleic
acid
protein
thu
ineffect
prion
pall
leukotrap
affin
prion
reduct
filter
system
pcapt
prion
reduct
filter
highli
specif
captur
remov
vcjd
prion
protein
filter
council
europ
ce
mark
technolog
time
public
remov
prion
red
blood
cell
commonli
transfus
blood
compon
one
technolog
treatment
red
cell
concentr
current
develop
util
lightindepend
alkyl
agent
frale
frangibl
anchor
linker
effector
ceru
corp
antivir
antibacteri
antiparasit
agent
molecul
compos
acridin
moieti
noncoval
intercal
nucleic
acid
structur
rna
dna
bound
acridinebas
intercal
structur
flexibl
labil
ester
linker
connect
bisalkyl
group
entiti
react
nucleotid
base
dna
rna
creat
crosslink
ester
hydrolyz
neutral
ph
result
nonreact
breakdown
product
includ
acridinebas
product
term
initi
usag
agent
prt
result
antibodi
format
acridin
moieti
addit
glutathion
quencher
second
gener
process
resolv
antibodi
format
issu
frale
phase
iii
clinic
trial
frale
system
util
red
cell
concentr
rcc
undergo
leukoreduct
follow
incub
glutathion
gsh
frale
pathogen
inactiv
process
occur
within
min
must
decompos
h
nonreact
byproduct
end
storag
averag
concentr
remain
product
approxim
lm
centrifug
remov
supernat
resuspens
addit
solut
sagm
rcc
store
refriger
day
undetect
level
remain
decomposit
wash
toxicolog
studi
parent
compound
neither
requir
regulatori
agenc
perform
toxicolog
studi
carri
degrad
product
howev
nucleic
acid
alkyl
agent
parent
compound
would
expect
genotox
nevertheless
advers
effect
observ
five
time
standard
dose
use
prepar
rbc
subsequ
transfus
rat
dog
model
discuss
clear
type
chemistri
use
prt
drive
effect
technolog
variou
blood
product
product
hydrophob
abil
perform
intracellularli
expand
effect
blood
product
nevertheless
prt
techniqu
difficulti
inactiv
sporeform
bacteria
bacillu
cereu
regardless
chemistri
util
variou
chemistri
impact
pathogen
inactiv
also
affect
plasma
cellular
protein
degre
mechan
result
vari
protein
qualiti
plasma
product
cell
qualiti
platelet
product
potenti
immunomodulatori
effect
briefli
describ
technolog
appear
differ
chemic
perspect
similar
none
technolog
chemistri
current
approv
commerci
use
treatment
product
contain
rbc
though
terumo
bct
ceru
proceed
trial
respect
product
work
ongo
ceru
corp
riboflavin
terumo
bct
adopt
prt
gradual
steadi
past
decad
everpres
threat
emerg
reemerg
infecti
diseas
well
risk
clinic
condit
relat
transfus
blood
product
drive
need
innov
new
technolog
field
blood
bank
transfus
medicin
henc
develop
prt
numer
technolog
mechan
discuss
paper
reflect
complex
find
balanc
effect
pathogen
inactiv
blood
product
maintain
accept
qualiti
function
hemostat
compon
develop
refin
techniqu
ongo
goal
creat
safer
global
blood
suppli
primari
indic
treatment
pathogen
reduct
transfus
blood
compon
applic
use
prt
explor
scope
investig
studi
includ
field
vaccin
develop
oncolog
biofilm
lyphol
veterinari
medicin
agricultur
applic
work
earliest
stage
explor
seem
clear
full
potenti
technolog
yet
determin
global
impact
prt
may
healthcar
scienc
realiz
decad
come
